New shot for IBS-C shows promise in Mid-Stage trial
NCT ID NCT07545772
First seen May 02, 2026 · Last updated Jun 19, 2026 · Updated 8 times
Summary
This Phase 2 trial tests brenipatide, a drug injected under the skin, in 342 adults with irritable bowel syndrome with constipation (IBS-C). The study compares brenipatide to a placebo to see if it safely reduces abdominal pain and improves bowel movements over about 35 weeks. Participants must meet specific symptom criteria, including moderate pain and hard stools.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONSTIPATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gastroenterology Health Partners Loc. 1
RECRUITINGLouisville, Kentucky, 40218, United States
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
brenipatide (a drug injected under the skin)
What this could lead to
If it works, this could point toward a new treatment option for people with constipation-predominant irritable bowel syndrome.
What could go wrong
This is an early Phase 2 trial, so it may not show enough benefit over placebo. Side effects are still being studied, and the drug may not reach the market for years, if at all.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.